Research programme: tissue factor pathway inhibitors - Affymax/EntreMed

Drug Profile

Research programme: tissue factor pathway inhibitors - Affymax/EntreMed

Latest Information Update: 27 Aug 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator EntreMed
  • Developer Affymax; EntreMed
  • Class Peptides
  • Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Thromboplastin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 21 Jul 2006 This programme is still in active development
  • 26 Oct 2004 EntreMed and Affymax have entered into an agreement to co-develop TFPI peptides for cancer
  • 17 Jun 2003 A preclinical study has been added to the Cancer pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top